Literature DB >> 16082249

Localization of mesothelin in epithelial ovarian cancer.

Raffit Hassan1, Robert J Kreitman, Ira Pastan, Mark C Willingham.   

Abstract

Mesothelin is a cell surface glycoprotein that is present on normal mesothelial cells and overexpressed in several cancers. On immunohistochemical examination of a limited number of ovarian tumors, increased mesothelin expression has been previously noted. The authors evaluated mesothelin expression in 48 patients with ovarian cancer who were screened for participation in phase 1 studies of a recombinant immunotoxin targeting mesothelin. Eligibility criteria for participation in the studies included mesothelin expression by more than 30% of accessible tumor cells. Sections of formalin-fixed paraffin-embedded tumor specimens were evaluated for mesothelin expression by immunohistochemistry using the anti-mesothelin monoclonal antibody K1. Between September 2000 and January 2003, 48 ovarian tumors were analyzed for mesothelin positivity. Mesothelin positivity was noted in 34 of the 48 cases evaluated (71%). These results show that mesothelin is expressed in most epithelial ovarian cancers and that mesothelin expression in ovarian cancers can be evaluated in archival material. Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082249     DOI: 10.1097/01.pai.00000141545.36485.d6

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  87 in total

1.  A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Authors:  Dung T Le; Dirk G Brockstedt; Ran Nir-Paz; Johannes Hampl; Shruti Mathur; John Nemunaitis; Daniel H Sterman; Raffit Hassan; Eric Lutz; Bentley Moyer; Martin Giedlin; Jana-Lynn Louis; Elizabeth A Sugar; Alice Pons; Andrea L Cox; Jordana Levine; Aimee Luck Murphy; Peter Illei; Thomas W Dubensky; Joseph E Eiden; Elizabeth M Jaffee; Daniel A Laheru
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Authors:  Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

3.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

4.  Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

Authors:  Ronit Mazor; Emily King; Ira Pastan
Journal:  Cell Immunol       Date:  2018-08-28       Impact factor: 4.868

Review 5.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

6.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 7.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

8.  Detecting Rare Mutations with Heterogeneous Effects Using a Family-Based Genetic Random Field Method.

Authors:  Ming Li; Zihuai He; Xiaoran Tong; John S Witte; Qing Lu
Journal:  Genetics       Date:  2018-08-13       Impact factor: 4.562

9.  Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Authors:  Jingli Zhang; Shuo Qiu; Yujian Zhang; Maria Merino; Patricia Fetsch; Itzhak Avital; Armando Filie; Ira Pastan; Raffit Hassan
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

Review 10.  Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Authors:  Takahiro Einama; Futoshi Kawamata; Hirofumi Kamachi; Hiroshi Nishihara; Shigenori Homma; Fumihiko Matsuzawa; Tatsuzo Mizukami; Yuji Konishi; Munenori Tahara; Toshiya Kamiyama; Okio Hino; Akinobu Taketomi; Satoru Todo
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.